NCLEX-style practice question
A client with cystic fibrosis has ventilator-associated pneumonia. Aztreonam 1 gm IV daily was prescribed for suspected Pseudomonas aeruginosa, but the culture now shows methicillin-resistant Staphylococcus aureus (MRSA). Which action should the nurse take next?
- Administer the aztreonam dose as scheduled because it covers MRSA.
- Notify the provider that aztreonam is not effective against MRSA and request review of the antimicrobial regimen.
- Hold all antibiotics until a repeat culture is obtained.
- Increase the infusion rate to improve coverage against the new organism.
Show answer and rationale
Correct answer: B. Notify the provider that aztreonam is not effective against MRSA and request review of the antimicrobial regimen.
Aztreonam is a monobactam with gram-negative activity, including Pseudomonas, and has no meaningful activity against gram-positive organisms such as MRSA. The nurse should promptly inform the provider so the prescriber can change to an agent active against MRSA. Simply giving the dose as scheduled is tempting because the infection is already being treated, but that leaves the MRSA untreated.
Adapted from Open RN Nursing Pharmacology, Chippewa Valley Technical College, CC BY 4.0.
Category: Pharmacological and Parenteral Therapies / Pharmacological Therapies · Topic: Pneumonia and respiratory infections